Recent Headlines
AnaSpec Introduces 13 New Antibody Products
AnaSpec added thirteen (13) new antibody products to its growing collection. - April 25, 2008 - AnaSpec, EGT Group
SensoLyte™ MMP Assay Kits Offer a New Industry Standard for Sensitivity
AnaSpec’s SensoLyte™ line of MMP assay kits have quickly become the new standard in MMP assay sensitivity. - April 24, 2008 - AnaSpec, EGT Group
AnaSpec FRET-Based MMP Substrates Used in Double Differential in Vivo Zymography
AnaSpec FRET-based MMP substrates were recently used in a double differential in vivo zymography study at the University of New Brunswick. - April 23, 2008 - AnaSpec, EGT Group
New Anti-MMP Antibodies Introduced by AnaSpec
AnaSpec has introduced its newest MMP antibodies. - April 11, 2008 - AnaSpec, EGT Group
AnaSpec Offers Fluo-3 - a High Affinity Fluorescent Calcium Indicator
Calcium plays a vital role in the specific and selective regulation of major cellular processes and is central in the regulation of cardiac contractility, growth and gene expression. Calcium indicators are small molecules that can respond to the binding of Ca2+ ions by changing their spectral... - March 29, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Suite of Labeled & Unlabeled Anti-Actin Antibodies
AnaSpec has introduced a suite of labeled and unlabeled anti-Actin antibodies. - March 26, 2008 - AnaSpec, EGT Group
AnaSpec Introduces New Technical Support Solution
This month AnaSpec introduced a significantly improved online technical support resource for its website users. AnaSpec's new Frequently Asked Questions (FAQ) Page now offers a searchable database of solutions that offers a more convenient and more comprehensive solution for technical support needs. - March 22, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Phosphopeptide Standards Kit
AnaSpec has introduced a dependable tool for the analysis and characterization of phosphorylated peptides – AnaSpec’s Phosphopeptide Standards Kit. - March 19, 2008 - AnaSpec, EGT Group
AnaSpec Introduces 58 New Antibody Products
Continuing to rapidly expand its antibody offerings, AnaSpec has added fifty-eight (58) new antibody products to its growing collection. Anti-PTEN (pSer385) (polyclonal) - Cat# 29642-025, 25 µg Host: rabbit polyclonal; Species Reactivity: human; rat; mouse; Applications: IP; WB;... - March 16, 2008 - AnaSpec, EGT Group
NCSRT Launches DiaSync for Improved Yield, Lower Cost in Harvest, Concentration, and Diafiltration of Biomolecules
At the Antibody Development and Production meeting in San Diego, CA March 12, 2008, NCSRT is launching its DiaSync process for biomolecules from fermentation, cell culture, or extraction. Utilizing concurrent processing technology and the patented SmartFlow™ TFF technology, DiaSync provides... - March 12, 2008 - NCSRT, Inc.
AnaSpec Introduces New SensoLyte™ Cathepsin D Activity Assay Kits
AnaSpec has introduced a new series of SensoLyte™ Cathepsin D Activity Assay Kits to address the issue of autofluorescence interference. - March 09, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Two Novel Amino Acids
AnaSpec has introduced two novel amino acids that offer additional tools and functionality for peptide chemists. - March 05, 2008 - AnaSpec, EGT Group
AnaSpec Introduces 9 New Antibody Products
AnaSpec added nine new antibody products to its growing collection. - February 28, 2008 - AnaSpec, EGT Group
Former Manchester City Lord Mayor Has Hope and Quality of Life Restored at New Beike Stem Cell Facility
Shenzhen Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com), the world leader in the use of umbilical cord stem cells to successfully treat a variety of illnesses, announced that Audrey Jones, the former Lord Mayor of Manchester, has returned today to the United Kingdom (UK) with... - February 26, 2008 - Shenzhen Beike Biotechnology Co., Ltd.
AnaSpec Introduces 5 New Peptide Synthesis Reagents
AnaSpec added five (5) new peptide synthesis reagents to its combinatorial chemistry collection. - February 24, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Collection of Channel Blocker Peptides
AnaSpec has introduced its selection of channel blocker peptides. - February 21, 2008 - AnaSpec, EGT Group
AnaSpec Introduces New Suite of Fluorescently Labeled GST & 6xHis Tag Antibodies
AnaSpec has introduced a suite of fluorescently labeled GST and 6X-His antibodies. These antibodies are labeled with a selection of dyes, including AnaSpec’s proprietary HiLyte FluorTM and HiLytePlusTM dyes, which span the visible spectrum. This gives researchers a wide range of wavelength... - February 16, 2008 - AnaSpec, EGT Group
AnaSpec Introduces 46 New Antibody Products
Continuing to rapidly expand its antibody offerings, AnaSpec added forty-six (46) new antibody products to its growing collection. Anti - GST Tag AMCA labeled - Cat# 29531-AMCA, 100 µg Host: mouse monoclonal; Application: IHC Anti - GST Tag Biotin labeled - Cat# 29531-BIOT, 100... - February 13, 2008 - AnaSpec, EGT Group
AnaSpec Introduces 21 New Anti-Tau Antibodies
AnaSpec has announced the release of 21 new anti-Tau antibodies. Complementing one of the world’s most comprehensive collections of beta-amyloid peptides, this new selection of anti-Tau antibodies demonstrates AnaSpec’s efforts to deliver new solutions for Alzheimer research. Tau is a... - February 11, 2008 - AnaSpec, EGT Group
NCSRT Presents SmartFlow™ TFF Performance Advantages Over Centrifugation and Microfiltration for Monoclonal Antibody Recovery, Concentration and Diafiltration
NCSRT is presenting “A comparison of product yield using either centrifugation and microfiltration or simultaneous membrane processing with SmartFlow™ TFF” at the Waterside Conference in Miami, FL. The data, generated by Viventia Biotech of Winnipeg, Manitoba, Canada, demonstrates... - February 08, 2008 - NCSRT, Inc.
AnaSpec Introduces 9 New Antibody Products
Continuing to rapidly expand its antibody offerings, AnaSpec added nine (9) new antibody products to its growing collection. Anti-AKT pan (IN) - Cat# 54320, 50 µg Host: rabbit polyclonal; Species Reactivity: human; mouse; rat; bovine; zebrafish; Applications: WB Anti-AKT pan (NT) - Cat#... - January 27, 2008 - AnaSpec, EGT Group
Xcelience Expands Its Early Drug Development Capabilities
The Tampa-based CRO is first to acquire next generation Xcelodose. - January 26, 2008 - Xcelience, LLC
AnaSpec Announces a Broad Selection of T-Cell Epitopes
AnaSpec has announced the availability of a wide selection of T-Cell Epitopes, available both individually and pooled. - January 23, 2008 - AnaSpec, EGT Group
Samaritan Announces the Granting of European Patent for New Type of Cardiovascular Plaque Clearing Drug SP-1000
Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. - January 09, 2008 - Samaritan Pharmaceuticals
Samaritan Pharma Strategically Advances Its Promising Alzheimer's Drug
Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan... - January 09, 2008 - Samaritan Pharmaceuticals
Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus
Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 09, 2008 - Samaritan Pharmaceuticals
Samaritan Pharmaceuticals Welcomes Two New Independent Directors to Its Board
Samaritan has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan's commitment to maintain a majority of independent members that reflects today's best practices on its Board. Samaritan's board is now comprised of eight independent directors and two internal directors. - January 09, 2008 - Samaritan Pharmaceuticals
FDA Accepts Samaritan's Cushing's SP-6300 IND and Clears Phase II Study
The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. - January 04, 2008 - Samaritan Pharmaceuticals
AnaSpec Introduces Ten New Catalog Peptides
This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced ten (10) new catalog peptides and one new unusual amino acid. MSL8; [Met256]-OVA (257-264)- Cat# 62573-5 Sequence: MSIINFEKL MSL8; [Met256]-OVA (257-264)- Cat# 62573-1 Sequence: MSIINFEKL OVA... - January 04, 2008 - AnaSpec, EGT Group
Samaritan Expands Revenue Opportunities with Marketing Authorization Approval for HIV Drug Amphocil in Cyprus
Samaritan Pharmaceuticals, Inc. is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification, from the Cyprus Ministry of Health, that its marketing authorization for HIV fungus drug Amphocil has been approved in Cyprus. The Cyprus Ministry of Health... - January 03, 2008 - Samaritan Pharmaceuticals
Actors Studio's Anna Strasberg Joins Samaritan Advisory Board of Directors
Ms. Anna Strasberg has joined Samaritan's Advisory Board. Anna Strasberg is best known for continuing the Actors Studio, where the work of her husband Lee Strasberg nurtured the talents of celebrities like Marlon Brando, Robert De Niro, Harvey Keitel, Paul Newman and Al Pacino. - January 03, 2008 - Samaritan Pharmaceuticals
Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus
Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 03, 2008 - Samaritan Pharmaceuticals
EUSA Pharma Signs Exclusive Distribution Agreement with Samaritan for Anesthetic Pain Patch to Launch and Sell in Greece and Cyprus
Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. - January 03, 2008 - Samaritan Pharmaceuticals
AnaSpec Introduces Sixteen New Catalog Peptides
This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced sixteen (16) new catalog peptides. [Cys17]-beta-Amyloid (1-17)- Cat# 62473 This peptide amino acids 1 to 17 is a modified fragment of the b-amyloid peptide; with cysteine substituted for valine... - December 20, 2007 - AnaSpec, EGT Group
AnaSpec Introduces First Colorimetric SensoLyte™ MMP Assay Kit
AnaSpec has introduced its first quantitative and homogeneous colorimetric MMP assay kit. - December 19, 2007 - AnaSpec, EGT Group
AnaSpec Introduces New Selection of Dye-Labeled Beta-Amyloid Peptides
AnaSpec introduces a new line of labeled amyloid peptides. - December 16, 2007 - AnaSpec, EGT Group
AnaSpec Introduces 10 New Catalog Antibodies
Continuing to rapidly expand its antibody offerings, AnaSpec added ten (10) new catalog antibodies to its growing collection. Anti-ATF2 (pT69/71) - Cat# 54323, 50 µg/250 µl Host: rabbit polyclonal; Species Reactivity: Human; Mouse; Rat; Zebrafish; Bovine; Applications: WB Anti-ATF2... - December 15, 2007 - AnaSpec, EGT Group
AnaSpec Releases New Antibodies Brochure
With a collection that has been rapidly expanded in the last few years, AnaSpec has organized its growing selection of antibodies into its newest antibodies brochure. The brochure showcases: • Primary antibodies • HRP, AP and biotin conjugated secondary antibodies • Patented... - December 14, 2007 - AnaSpec, EGT Group
Cardiovascular Sciences, Inc. Announces Funding Event
Cardiovascular Sciences, Inc. (CVSC), a corporation under the laws of Nevada, is excited to reveal an initial funding event with Seven Palm Investments, LLC of Illinois. After a recent assessment and restructuring of the company’s equity, the company and its investors are ready to move ahead... - December 12, 2007 - Cardiovascular Sciences, Inc.
AnaSpec Introduces Eight New Catalog Peptides and One Unusual Amino Acid
This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced eight (8) new catalog peptides and one new unusual amino acid. - December 07, 2007 - AnaSpec, EGT Group
AnaSpec Introduces New Collection of Bcl Peptides
AnaSpec introduced a collection of peptides related to the family of proteins called Bcl-2 (B-cell lymphoma 2) for use in cancer research or cell cycle research. - December 06, 2007 - AnaSpec, EGT Group
AnaSpec Introduces 17 New Anti-Tau Antibodies
Continuing to rapidly expand its antibody offerings, AnaSpec added seventeen (17) new anti-Tau antibodies to its growing collection. Anti-Tau (paired181) - Cat# 54961, 50 µg Host: rabbit polyclonal; Species Reactivity: Human; Mouse; Rat; Applications: WB Anti-Tau (paired198;199;202;205) -... - December 06, 2007 - AnaSpec, EGT Group
AnaSpec Celebrates the Holidays with Its Customers
AnaSpec will be adding a one pound box of See’s Candy into every order placed from now through the end of the year. - November 29, 2007 - AnaSpec, EGT Group
AnaSpec Introduces AnaTagTM Protein Labeling Kits with HiLytePlusTM
AnaSpec introduced a new series of AnaTagTM Labeling Kits now available with the revolutionary new HiLytePlus™ series of long-wavelength dyes. - November 29, 2007 - AnaSpec, EGT Group
Samaritan Presented Favorable Caprospinol Data at Alzheimer's Drug Development Summit
In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's, but may also reverse plaque-related brain injuries associated with AD. - November 27, 2007 - Samaritan Pharmaceuticals
AnaSpec Introduces HiLytePlus™ Labeled Secondary Antibodies & Streptavidin
AnaSpec introduces a new collection of secondary antibodies and streptavidin labeled with the new HiLytePlus™ series of fluorescent dyes. - November 17, 2007 - AnaSpec, EGT Group
AnaSpec Introduces Thirteen New Catalog Peptides
Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced thirteen (13) new catalog peptides. Bak BH3 (71-89)- Cat# 62261 This peptide is amino acids 71 to 89 fragment of the Bak BH3 domain .The BH3 domain plays a critical role in mediating the cell death... - November 11, 2007 - AnaSpec, EGT Group
AnaSpec Introduces HiLytePlus™ – AnaSpec’s Highest Performance Fluorescent Dyes
This week AnaSpec announced the release of the HiLytePlus™ series of fluorescent dyes. Demonstrating even greater brightness than AnaSpec’s HiLyte Fluor™ line, this series represents the next generation in AnaSpec’s line of high performance fluorescent dyes. With excitation... - November 09, 2007 - AnaSpec, EGT Group
Xcelience’s Scientific Director Selected to Lead Key Sessions on Upcoming Conferences
Dr. Steve Bannister’s expertise requested for several speaking engagements over the next year - October 31, 2007 - Xcelience, LLC
NCSRT Introduces WORKS™, an Integrated Program of Products, Applications Guides, Optimization Tools, and Services
NCSRT Introduces WORKS™, an integrated program of products, applications guides, optimization tools, and services to dramatically improve downstream processing in the biopharmaceutical production environment. With the patented SmartFlow™ TFF modules and industry leading PUROSEP®... - October 30, 2007 - NCSRT, Inc.